Introduction {#sec1-1}
============

Squamous cell carcinoma of the head and neck (SCCHN) is the sixth leading cancer by incidence worldwide.\[[@ref1]\] Cigarette smoking and alcohol are the major causative factors for SCCHN in the Western population,\[[@ref2]\] whereas the use of smokeless tobacco, betel nut, and Epstein--Barr virus are common factors responsible in the Asian population.\[[@ref3][@ref4][@ref5]\]

Most of the cases of SCCHN present in locally advanced stage and often tend to recur either locally or develop metastatic disease despite receiving standard treatment.\[[@ref4][@ref6][@ref7]\] Patients with recurrent and/or metastatic (R/M) SCCHN have a poor prognosis and outcome. Palliative systemic chemotherapy with or without radiation therapy remains the mainstay of treatment. Platinum-based chemotherapy/5-fluorouracil (5-FU)/taxane-based regimens are the preferred standard treatment in the management of in unresectable and recurrent/metastatic SCCHN.\[[@ref4][@ref8][@ref9][@ref10]\] Despite advances in systemic chemotherapy regimens, the overall survival (OS) rate is low in recurrent/metastatic SCCHN.\[[@ref10]\]

Epidermal growth factor receptor (EGFR) is highly expressed in more than 90% of all cases of SCCHN, and this expression is correlated with poor prognosis, including decreased survival, resistance to radiotherapy (RT), locoregional treatment failure, and increased metastatic potential.\[[@ref11]\]

Thus, inhibition of EGFR signaling represents a novel and rational approach in SCCHN therapeutics. Anti-EGFR monoclonal antibodies (MAbs) have attracted attention as potential candidates in the treatment of SCCHN. Anti-EGFR mAbs, cetuximab and nimotuzumab, are approved molecules and have shown promising results with the improvement in progression-free survival and OS in patients with SCCHN.\[[@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22]\] Cetuximab is a chimeric human/murine anti-EGFR mAb. In 2008, the Phase III EXTREME trial demonstrated that the addition of cetuximab to first-line platinum/5-FU chemotherapy significantly leads to a prolonged median progression-free survival of 2.3 months and improved median survival from 7.4 to 10.1 months (*P* = 0.03) compared with platinum-based chemotherapy alone in recurrent and/or metastatic SCCHN.\[[@ref17]\] This was the first combination therapy to show a survival benefit over platinum-based chemotherapy in recurrent and/or metastatic SCCHN and has been accepted as standard of care. Overall, cetuximab is associated with a favorable toxicity profile, but safety concerns are raised due to immunogenicity, severe skin toxicity, electrolyte imbalance, infusion reactions, and gastrointestinal adverse events (AEs).\[[@ref16][@ref23][@ref24]\]

Nimotuzumab (BIOMAb EGFR^®^) is a humanized anti-EGFR mAb. The BEST trial demonstrated that the addition of nimotuzumab to chemo-RT (CRT) or RT provided with long-term survival benefit in inoperable, locally advanced SCCHN.\[[@ref18]\]

At present, the clinical efficacy and safety of nimotuzumab in LA-SCCHN are well established, and several authors have documented that the addition of the nimotuzumab to various standard treatments (RT or chemotherapy or CRT) improved the tumor response rate and survival with minimal toxicities in LA-SCCHN.\[[@ref18][@ref20][@ref25][@ref26][@ref27][@ref28][@ref29]\]

However, in recurrent and metastatic SCCHN setting, the clinical evidence on efficacy and survival benefits achieved by the addition of nimotuzumab to standard treatment is not available and needs to be explored. Therefore, in the present study, we retrospectively analyzed the effectiveness, survival benefits, and tolerability of nimotuzumab in combination with investigator\'s choice of standard/conventional treatment in Indian patients with recurrent and/or metastatic SCCHN.

Subjects and Methods {#sec1-2}
====================

This retrospective study evaluated the effectiveness and tolerability of nimotuzumab with standard treatment. The hospital records of recurrent/metastatic SCCHN patients who received nimotuzumab in combination with standard/conventional treatment from December 2010 to December 2016 at VS Hospital and Cancer Center, India, were reviewed. The study was approved by the Institutional Review Board.

We selected cases based on the following eligibility criteria: (a) patients aged 18 years and above, (b) patients with recurrent and/or metastatic carcinoma of the head and neck, (c) histologically confirmed squamous cell carcinoma (d) patients with the Eastern Cooperative Oncology Group (ECOG) performance score ≤2, and (e) patients treated with nimotuzumab (200 mg weekly) combined with standard treatment. We excluded patients of nonhead and neck cancer (HNC), salivary gland cancer, paranasal sinus cancer, and nasopharyngeal cancer and treated before any other anti-EGFR-based therapy. The information was collected from the hospital records of individual patients. Clinical data of patients were collected, including diagnosis, age, gender, pathological type, anatomical subsites, tumor stage, tumor extent, ECOG status, and clinical course of the disease with details of standard treatment and nimotuzumab therapy.

Evaluating parameters {#sec2-1}
---------------------

OS was calculated from the date of diagnosis to the date of death or last contact (visit and telephone). Tumor response was calculated as per the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Complete remission (CR), partial remission (PR), stable disease, progressive disease (PD), and objective response rate (ORR) were calculated. All AEs were collected and graded by the National Cancer Institute\'s Common Toxicity Criteria version 4.

Statistical analysis {#sec2-2}
--------------------

Statistical analysis was performed using STATA software (version. 12, StataCorp., College Station, TX: USA). Data were expressed in descriptive statistics. Median OS along with 95% confidence interval (CI) was estimated by the Kaplan--Meier method.

Results {#sec1-3}
=======

The hospital records of 14 patients diagnosed with recurrent and/or metastatic HNC with histologically confirmed squamous cell carcinoma and treated with nimotuzumab from December 2010 to December 2016 were retrospectively identified. The mean age of the enrolled patients was 57.71 ± 14.6 years, with 12 males (86%) and 2 females (14%). The most common anatomical site of the tumor was oral cavity (35.7%), followed by oropharynx (28.6%) and hypopharynx (21.4%). Majority of the patients had a good ECOG performance status (0--1). The baseline characteristics and type of standard combination treatment in recurrent and metastatic SCCHN patients are listed in [Table 1](#T1){ref-type="table"}.

###### 

Baseline characteristics of patients with unresectable recurrent and metastatic squamous cell carcinoma of the head and neck

![](SAJC-7-188-g001)

Effectiveness {#sec2-3}
-------------

### Survival outcome {#sec3-1}

In this retrospective study, we observed that OS at 1, 2, and 3 years was 77.80% (95% CI: 36.48--93.93), 64.81% (95% CI: 25.32--87.21), and 64.81% (95% CI: 25.32--87.21), respectively. At a median follow-up of 15.17 months, median OS was not reached \[[Figure 1](#F1){ref-type="fig"}\].

![Kaplan--Meier method estimates of overall survival in recurrent and metastatic squamous cell carcinoma of the head and neck on treatment](SAJC-7-188-g002){#F1}

### Tumor response {#sec3-2}

At 24 weeks after completion of treatment, the tumor response rate observed was as follows: 16.7% of patients had a complete response (CR), 58.3% of patients had partial response (PR), and 25% of patients had progressive disease (PD) response. ORR was 75% \[[Table 2](#T2){ref-type="table"}\].

###### 

Overall tumor response in patients treated with nimotuzumab and standard treatment (*n*=12)
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Safety and toxicity {#sec2-4}
-------------------

The most common AEs encountered during nimotuzumab treatment were mucositis (27.7%), followed by vomiting (22.2%). All AEs were either Grade I (66.7%) or Grade II (33.3%). The detailed toxicity and their grades are summarized in [Table 3](#T3){ref-type="table"}. No Grade III, IV, and V toxicities were observed. Nimotuzumab was observed to be safe with no added toxicity reported.

###### 

Common adverse events encountered during the treatment
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Discussion {#sec1-4}
==========

The findings of the present retrospective study indicate that the addition of nimotuzumab to investigator\'s choice of standard treatment raised the tail of the survival curve, which signifies an improved survival rate in unresectable, recurrent and/or metastatic SCCHN.

Recurrent and metastatic SCCHN is a rising problem in India and a clinical challenge to manage despite the treatment options and strategies currently available.\[[@ref4]\] Recurrent and metastatic SCCHN carries a poor prognosis with a median OS less than a year. Most patients with R/M SCCHN qualify either for palliative chemotherapy or best supportive care as surgery and RT are generally not an option.\[[@ref10]\]

Palliative systemic chemotherapy with or without radiation therapy remains the mainstay of treatment in recurrent/metastatic, unresectable with the disease. The choice of chemotherapy depends on patient characteristics, side-effect profile, and patient performance status. Platinum-based chemotherapy and platinum/5-FU/taxane-based regimes are currently the standard of care in the management of SCCHN that is recurrent, metastatic, unresectable, and considered incurable.\[[@ref4][@ref8][@ref9][@ref10]\] Unfortunately, the survival outcome is dismal, and efforts to improve the outcomes have led to molecular biology-based targeted therapy.

EGFR represents a novel molecular target in HNCs. The overexpression of the EGFR levels is closely related to tumor cell growth, proliferation, invasion, metastasis, apoptosis, and poor prognosis. Thus, inhibition of EGFR leads to inhibition of tumor cell proliferation, differentiation, and tumor angiogenesis and also improves the treatment response of chemotherapy and radiation.\[[@ref30]\]

The EXTREME trial demonstrated that the addition of the EGFR-targeted monoclonal antibody, cetuximab to first-line platinum, and 5-FU chemotherapy significantly leads to a prolonged median progression-free survival of 2.3 months (hazard ratio \[HR\] for progression, 0.54; *P* \< 0.001), improved OS by 2.7 months (10.1 vs. 7.4 months for platinum-based chemotherapy alone), and improved the chance of a response compared with platinum-based chemotherapy alone in recurrent and/or metastatic SCCHN.\[[@ref16][@ref17]\]

In general, cetuximab has been accepted as standard of care in recurrent and/or metastatic SCCHN, but safety concerns are raised due to immunogenicity, severe skin toxicity, electrolyte imbalance, infusion reactions, and gastrointestinal AEs.\[[@ref16][@ref23][@ref24]\] In the clinical trial by Vermorken *et al*., comparing chemotherapy versus chemotherapy plus cetuximab, there was 20% discontinuation rate due to toxicities in the chemotherapy plus cetuximab group with nine cases of sepsis.\[[@ref16]\] Similarly, other anti-EGFR mAbs also have potential risk and safety concerns.\[[@ref16][@ref23][@ref24]\]

Nimotuzumab (BIOMAb EGFR^®^) is a humanized anti-EGFR mAb that binds to the extracellular domain of EGFR with intermediate affinity and high specificity which results in the blockade of receptor-dependent signal transduction pathways and provides antitumor efficacy.\[[@ref18][@ref31]\] It also enhances the tumor radiosensitivity by inhibiting the radiation-induced activation of DNA-PKcs by blocking the PI3K/AKT pathway.\[[@ref32]\]

Nimotuzumab unique benign low toxicity profile can be attributed to the fact that unlike other anti-EGFR antibodies, it requires bivalent binding for stable attachment, leading to selective binding to tumors cells that overexpress the EGFR (moderate to high) level. When EGFR expression is low, such as in normal tissues, monovalent interaction of nimotuzumab is transient, thus sparing normal healthy tissues and avoiding severe toxicities.\[[@ref33]\] This probably explains the minimal toxicities associated with nimotuzumab therapy.

The promising therapeutic and survival outcomes documented in the BEST trial strongly favored and laid the foundation for nimotuzumab as an add-on therapy to standard treatments in LA-SCCHN.\[[@ref18]\] The BEST trial was a multicenter, randomized, open-label, Phase IIb, 5-year study and the first of its kind cohort conducted among the Indian population.\[[@ref11]\] The study evaluated the safety and efficacy of nimotuzumab, administered along with CRT or RT in patients with inoperable, locally advanced SCCHN. The trial documented that the 5-year OS was significantly higher in the nimotuzumab + CRT group than in the CRT group (57% vs. 26%, *P* = 0.03). The median 5-year OS was not reached in the nimotuzumab + CRT group at 60 months, whereas it was 21.94 months in the CRT group (*P* = 0.0078); the addition of nimotuzumab to CRT caused a 64% reduction in death risk (HR = 0.36, 95% CI: 0.37, 1.56). The 5-year OS was 39% (95% CI: 19.71, 61.46) in the nimotuzumab + RT group versus 26% (95% CI: 10.23, 48.41; *P* \> 0.05) in the RT group. Nimotuzumab was found to be safe and well tolerated with few mild-to-moderate self-limiting AEs. No long-term drug-related toxicity was seen during the median follow-up of 65.7 months. Results of the BEST trial strongly suggested that nimotuzumab improved locoregional control and prolonged survival when used along with RT or CRT.\[[@ref18]\]

In India, several authors in their individual research have documented that the addition of nimotuzumab to various standard treatment/combined treatment strategies (RT or chemotherapy or concurrent chemoradiation) in LA-SCCHN improved tumor response rate and survival outcomes with minimal toxicities.\[[@ref19][@ref20][@ref25][@ref26][@ref27][@ref28][@ref29]\] However, its role in recurrent and metastatic SCCHN setting is not well explored.

To the best of our knowledge, there is no published literature of Indian patients regarding the use of nimotuzumab in recurrent and metastatic SCCHN. This is the first kind of retrospective study, which provides evidence on the effectiveness, survival benefits, and tolerability of nimotuzumab with investigator\'s choice of standard care therapy/conventional treatment in Indian patients with recurrent and metastatic SCCHN.

In the present retrospective study, we found that addition of nimotuzumab to the standard treatment resulted in improved survival rates in unresectable, recurrent, and metastatic SCCHN. The OS benefit achieved with the add-on combination at 1, 2, and 3 years was 77.80%, 64.81%, and 64.81%, respectively. At a median follow-up of 15.17 months, median OS was not reached.

Our findings of improved survival benefit in recurrent and metastatic SCCHN are similar to survival benefit observed in LA-SCCHN setting.\[[@ref18][@ref20][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30]\] The improved OS achieved with the addition of nimotuzumab to the standard treatment in the present analysis is higher than the documented landmark EXTREME cetuximab study.\[[@ref17]\] Thus, nimotuzumab as an add-on to standard treatment can be a promising option in recurrent and metastatic SCCHN.

In the present study, the common AEs observed during treatment were mucositis, followed by vomiting, which are similar to documented studies with nimotuzumab.\[[@ref11][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20]\] All AEs were either Grade I or Grade II. No Grade III, IV, and V AEs were observed. No typical anti-EGFR-related toxicity such as severe skin rash, infusion reactions, or hypomagnesemia was observed. Nimotuzumab was observed to be safe with no additional potentiating AEs encountered.

The study had the following limitations; first, the study design was retrospective with a single-arm assessment. Second, the analyzed retrospective data included heterogeneous standard treatment regimens, and third, the sample size was small.

Conclusions {#sec1-5}
===========

In the first of its kind study, the addition of nimotuzumab to standard treatment showed promising survival outcomes as well as the response rate in recurrent/metastatic SCCHN patients without producing additional toxicity. Robust multicenter, randomized trials are warranted to validate these interesting findings.
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